SPR Therapeutics receives CE mark for peripheral nerve stimulation therapy

SPR Therapeutics announced that it has received CE mark for its Smartpatch system, a peripheral nerve stimulation therapy for the minimally invasive treatment of pain.

According to a company press release, the Smartpatch system was developed to address a spectrum of pain indications, including acute and chronic musculoskeletal pain.

With electrodes positioned in proximity to, but not directly contacting, peripheral nerves, SPR’s pain therapy platform is non-narcotic, reversible and has demonstrated significant pain relief in multiple studies. The therapy is intended to be used up to 30 days, however, clinical trials have reported that most patients experienced pain relief beyond the 30-day treatment period, according to the release.

“We will be using the CE mark to further develop clinical data and clinician advocacy in support of our shoulder pain indication through orthopedic, pain management, physical medicine and rehabilitation channels in Europe and to expand to other geographies in the future,” Maria Bennett, president and chief executive officer of SPR Therapeutics, stated. “Toward this end, we are in discussions with corporate strategic partners to commercialize Smartpatch outside the United States.”